Abstract
The People's Republic of China represents a rapidly expanding pharmaceutical market with the potential to become a major player in pharmaceutical development. As the Chinese government moves forward in its campaign to build a modern pharmaceutical industry, it is instructive to examine issues in global drug development. This paper reviews various factors that have an impact on new drug development, including time and cost estimates for bringing a new product to market, and considers several global initiatives designed to facilitate pharmaceutical innovation.
Keywords
Get full access to this article
View all access options for this article.
References
1.
Bryant
R
Song
J.
China—from self-sufficiency to world leadership . Scrip Magazine. Sep 1997 ;60 : 58 –61 .
2.
Wong
E.
Clinical research in China . Drug Inf J.
1997 ;31 (1 ):93 –95 .
3.
Kaitin
KI
The Prescription Drug User Fee Act of 1992 and the new drug development process . Am J Ther. May 1997 ;4 (5/6 ): 167 –172 .
4.
DiMasi
JA
Success rates for new drugs entering clinical testing in the United States . Clin Pharmacol Ther. July 1995 ;58 (1 ):1 –14 .
5.
DiMasi
JA
Hansen
RW
Grabowski
HG
Lasagna
L.
Cost of innovation in the pharmaceutical industry . J Health Econ. Feb 1991 ;10 (2 ):107 –142 .
6.
Kaitin
KI
FDA reform: Setting the stage for efforts to reform the agency . Drug Inf J.
1997 ;31 (1 ):27 –33 .
7.Major steps towards global drug regulations.
Health Horizons. Autumn 1997 ;#32 :10 –11 .
8.Food and Drug Modernization Act of 1997. (PL 105–115) 111 Stat. 2296.